# Tofacitinib in Recurrent GBM Patients

> **NCT05326464** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 17 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Tofacitinib 10mg

## Key facts

- **NCT ID:** NCT05326464
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-10-07
- **Primary completion:** 2025-06-16
- **Final completion:** 2027-06-01
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2025-12-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05326464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05326464, "Tofacitinib in Recurrent GBM Patients". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05326464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*